These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1084 related articles for article (PubMed ID: 15748426)
21. Common defects of different retinoic acid resistant promyelocytic leukemia cells are persistent telomerase activity and nuclear body disorganization. Nason-Burchenal K; Maerz W; Albanell J; Allopenna J; Martin P; Moore MA; Dmitrovsky E Differentiation; 1997 Aug; 61(5):321-31. PubMed ID: 9342843 [TBL] [Abstract][Full Text] [Related]
22. Successful all-trans retinoic acid treatment of acute promyelocytic leukemia in a patient with NPM/RAR fusion. Okazuka K; Masuko M; Seki Y; Hama H; Honma N; Furukawa T; Toba K; Kishi K; Aizawa Y Int J Hematol; 2007 Oct; 86(3):246-9. PubMed ID: 17988991 [TBL] [Abstract][Full Text] [Related]
23. Mechanisms of all-trans retinoic acid-induced differentiation of acute promyelocytic leukemia cells. Zhang JW; Wang JY; Chen SJ; Chen Z J Biosci; 2000 Sep; 25(3):275-84. PubMed ID: 11022230 [TBL] [Abstract][Full Text] [Related]
24. Mutations in the E-domain of RAR portion of the PML/RAR chimeric gene may confer clinical resistance to all-trans retinoic acid in acute promyelocytic leukemia. Imaizumi M; Suzuki H; Yoshinari M; Sato A; Saito T; Sugawara A; Tsuchiya S; Hatae Y; Fujimoto T; Kakizuka A; Konno T; Iinuma K Blood; 1998 Jul; 92(2):374-82. PubMed ID: 9657734 [TBL] [Abstract][Full Text] [Related]
26. Understanding the molecular pathogenesis of acute promyelocytic leukemia. Lo-Coco F; Hasan SK Best Pract Res Clin Haematol; 2014 Mar; 27(1):3-9. PubMed ID: 24907012 [TBL] [Abstract][Full Text] [Related]
27. Missense mutations in the PML/RARalpha ligand binding domain in ATRA-resistant As(2)O(3) sensitive relapsed acute promyelocytic leukemia. Marasca R; Zucchini P; Galimberti S; Leonardi G; Vaccari P; Donelli A; Luppi M; Petrini M; Torelli G Haematologica; 1999 Nov; 84(11):963-8. PubMed ID: 10553155 [TBL] [Abstract][Full Text] [Related]
28. Novel treatment of acute promyelocytic leukemia: As₂O₃, retinoic acid and retinoid pharmacology. Zhu G Curr Pharm Biotechnol; 2013; 14(9):849-58. PubMed ID: 24433507 [TBL] [Abstract][Full Text] [Related]
30. The aberrant fusion proteins PML-RAR alpha and PLZF-RAR alpha contribute to the overexpression of cyclin A1 in acute promyelocytic leukemia. Müller C; Yang R; Park DJ; Serve H; Berdel WE; Koeffler HP Blood; 2000 Dec; 96(12):3894-9. PubMed ID: 11090075 [TBL] [Abstract][Full Text] [Related]
31. Reduced and altered DNA-binding and transcriptional properties of the PLZF-retinoic acid receptor-alpha chimera generated in t(11;17)-associated acute promyelocytic leukemia. Licht JD; Shaknovich R; English MA; Melnick A; Li JY; Reddy JC; Dong S; Chen SJ; Zelent A; Waxman S Oncogene; 1996 Jan; 12(2):323-36. PubMed ID: 8570209 [TBL] [Abstract][Full Text] [Related]
32. Characterization of the retinoid binding properties of the major fusion products present in acute promyelocytic leukemia cells. Benedetti L; Levin AA; Scicchitano BM; Grignani F; Allenby G; Diverio D; Lo Coco F; Avvisati G; Ruthardt M; Adamo S; Pelicci PG; Nervi C Blood; 1997 Aug; 90(3):1175-85. PubMed ID: 9242550 [TBL] [Abstract][Full Text] [Related]
33. The PML-RAR alpha gene product of the t(15;17) translocation inhibits retinoic acid-induced granulocytic differentiation and mediated transactivation in human myeloid cells. Rousselot P; Hardas B; Patel A; Guidez F; Gäken J; Castaigne S; Dejean A; de Thé H; Degos L; Farzaneh F Oncogene; 1994 Feb; 9(2):545-51. PubMed ID: 8290265 [TBL] [Abstract][Full Text] [Related]
34. Molecular mechanisms of the antileukemia activities of retinoid and arsenic. Nitto T; Sawaki K J Pharmacol Sci; 2014; 126(3):179-85. PubMed ID: 25319615 [TBL] [Abstract][Full Text] [Related]
35. Targeting the PML/RAR alpha translocation product triggers apoptosis in promyelocytic leukemia cells. Nason-Burchenal K; Takle G; Pace U; Flynn S; Allopenna J; Martin P; George ST; Goldberg AR; Dmitrovsky E Oncogene; 1998 Oct; 17(14):1759-68. PubMed ID: 9778041 [TBL] [Abstract][Full Text] [Related]
36. Synergistic Leukemia Eradication by Combined Treatment with Retinoic Acid and HIF Inhibition by EZN-2208 (PEG-SN38) in Preclinical Models of PML-RARα and PLZF-RARα-Driven Leukemia. Coltella N; Valsecchi R; Ponente M; Ponzoni M; Bernardi R Clin Cancer Res; 2015 Aug; 21(16):3685-94. PubMed ID: 25931453 [TBL] [Abstract][Full Text] [Related]
37. Distinct leukemia phenotypes in transgenic mice and different corepressor interactions generated by promyelocytic leukemia variant fusion genes PLZF-RARalpha and NPM-RARalpha. Cheng GX; Zhu XH; Men XQ; Wang L; Huang QH; Jin XL; Xiong SM; Zhu J; Guo WM; Chen JQ; Xu SF; So E; Chan LC; Waxman S; Zelent A; Chen GQ; Dong S; Liu JX; Chen SJ Proc Natl Acad Sci U S A; 1999 May; 96(11):6318-23. PubMed ID: 10339585 [TBL] [Abstract][Full Text] [Related]
38. [Acute promyelocytic leukemia, histone deacetylase, and response to retinoids]. Jeanteur P Bull Cancer; 1998 Apr; 85(4):301-3. PubMed ID: 9752292 [TBL] [Abstract][Full Text] [Related]
39. Pulsed-field gel electrophoresis analysis of retinoic acid receptor-alpha and promyelocytic leukemia rearrangements. Detection of the t(15;17) translocation in the diagnosis of acute promyelocytic leukemia. Xiao YH; Miller WH; Warrell RP; Dmitrovsky E; Zelenetz AD Am J Pathol; 1993 Nov; 143(5):1301-11. PubMed ID: 8238249 [TBL] [Abstract][Full Text] [Related]